Antonucci Laura, Li Na, Duran Angeles, Cobo Isidoro, Nicoletti Chiara, Watari Kosuke, Nandi Shuvro Prokash, Zhu Feng, Zhao Yongmei, Riahi Irene, Tsuda Motoyuki, Shah Vidhi M, Morgan Terry, Waugh Trent, Caputo Luca, Liu Yuan, Rundberg Nilsson Alexandra, Xian Hongxu, Todoric Jelena, Gu Li, Sanchez-Lopez Elsa, Eibl Guido, Vucic Emily A, Krawczyk Michal, Xu Qianlan, Lowy Andrew M, Hatzivassiliou Georgia, Roose-Girma Merone, Skowronska-Krawczyk Dorota, Scott David A, Bar-Sagi Dafna, Tamayo Pablo, Wu Ying, Sears Rosalie C, Glass Christopher K, Alexandrov Ludmil B, Puri Pier Lorenzo, Dawson David W, Hu Yinling, Diaz-Meco Maria T, Moscat Jorge, Karin Michael
Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and Pathology, University of California, San Diego School of Medicine, La Jolla, CA, USA.
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, China.
Nat Cancer. 2025 Jun 30. doi: 10.1038/s43018-025-01003-3.
Pancreatic ductal adenocarcinoma (PDAC) emerges from mutant KRAS-harboring but dormant low-grade pancreatic intraepithelial neoplasia (PanIN). To examine the role of oxidative stress, a putative PDAC risk factor, we established an organoid-based transformation system. Although the prototypic oxidant HO induced organoid transformation, its effect was nonmutational and was mediated by the oxidant-responsive transcription factor NRF2, which induced the histone methyltransferase EZH2. Congruently, nonoxidizing NRF2 activators triggered organoid malignant conversion through NRF2 and EZH2, establishing a hitherto unknown epigenetic mechanism underlying PanIN-to-PDAC progression. While NRF2 induced EZH2 gene transcription in mouse and human PDAC, EZH2, a general repressor, coactivated transcription of NRF2-encoding NFE2L2 and interacted with other transcription factors to induce genes that sustain PDAC metabolic demands. The self-amplifying NRF2-EZH2 epigenetic loop also accounted for inflammation-driven PanIN-to-PDAC progression in vivo and was upregulated in established human PDAC, whose malignancy was maintained by NRF2 binding to the EZH2 promoter.
胰腺导管腺癌(PDAC)起源于携带突变KRAS但处于休眠状态的低级别胰腺上皮内瘤变(PanIN)。为了研究氧化应激(一种公认的PDAC风险因素)的作用,我们建立了一种基于类器官的转化系统。虽然典型的氧化剂HO诱导了类器官转化,但其作用是非突变性的,且由氧化应激反应转录因子NRF2介导,NRF2可诱导组蛋白甲基转移酶EZH2。同样,非氧化性NRF2激活剂通过NRF2和EZH2触发类器官恶性转化,确立了一种此前未知的PanIN向PDAC进展的表观遗传机制。虽然NRF2在小鼠和人类PDAC中诱导EZH2基因转录,但作为一种普遍的阻遏物,EZH2共同激活了编码NRF2的NFE2L2的转录,并与其他转录因子相互作用以诱导维持PDAC代谢需求的基因。这种自我放大的NRF2 - EZH2表观遗传环也解释了体内炎症驱动的PanIN向PDAC的进展,并且在已确诊的人类PDAC中上调,其恶性程度通过NRF2与EZH2启动子的结合得以维持。